Tolcher

Vincerx Pharma To Host Key Opinion Leader Webinar on Bioconjugation and CDK9 Inhibitors for the Treatment of Hematologic and Solid Tumors

Retrieved on: 
Wednesday, April 7, 2021
Medicine, Clinical medicine, Medical specialties, Immunology, Antineoplastic drugs, Brian Druker, Antibody-drug conjugate, Knight Cancer Institute, Tolcher, Forward-looking statement, Cancer

The event will feature presentations by KOLs Brian Druker, M.D., Knight Cancer Institute, and Anthony W. Tolcher, M.D., NEXT Oncology.

Key Points: 
  • The event will feature presentations by KOLs Brian Druker, M.D., Knight Cancer Institute, and Anthony W. Tolcher, M.D., NEXT Oncology.
  • Dr. Tolcher will discuss tackling normal tissue toxicity from antibody-drug conjugates (ADCs) and Dr. Druker will discuss CDK9 in hematologic malignancies.
  • Druker and Tolcher will be available to answer questions following the formal presentations.
  • Forward -looking statements speak only as of the date hereof, and Vincerx disclaims any obligation to update any forward-looking statements.